Dynamic monitoring of ctDNA and prediction of immune efficacy in advanced NSCLC patients with wild-type gene and feasibility study based on ctDNA level intervention
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TACTC-2
- 09 Jan 2025 New source identified and integrated (Chinese Clinical Trial Register: ChiCTR2100052222).
- 09 Jan 2025 New trial record
- 17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress